Citius Oncology, Inc.
CTORNASDAQHealthcareMedical - Pharmaceuticals
Previous close
$0.7438
−$0.0153 · -2.02%
CTOR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
41
Fair Value
Momentum
19
Strong Down
Sentiment
44
Mixed
Risk resilience
3
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCitius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Leonard L. Mazur
- Listed since
- Dec 8, 2022
- Employees
- 285
Market position
Day range
Current $0.7438
52-week range
Current $0.7438
- Open
- $0.7532
- Previous close
- $0.7591
- Volume
- 13.46K
- 0.15× average
- Average volume
- 91.26K
- Average daily volume
- Market cap
- 69.16M USD
- Beta
- 3.49
- Market reference 1
- 50-day average
- $0.6808
- +9.26% above average
- 200-day average
- $0.9265
- -19.72% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 148.61M USD
- P/E (TTM)
- -1.56×
- P/B (TTM)
- 1.99×
- P/S (TTM)
- 9.73×
- EV / EBITDA
- -6.33×
- Earnings yield
- -16.65%
- Free cash flow yield
- -3.69%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 53.13%
- Operating margin
- -665.63%
- Net margin
- -648.32%
- Return on equity
- -55.19%
- Return on assets
- -24.53%
- Return on invested capital
- -45.72%
Financial health
- Debt / equity
- 0.25×
- Current ratio
- 0.56×
Earnings
- EPS beat rate
- 25%
- 2 beats, 5 misses, 1 met estimate
- Average EPS surprise
- -334.94%
- 8 comparable reports
- Latest EPS result
- -0.08
- Estimate -0.07 · Miss by 14.29%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
CTOR peers
ETFs holding CTOR
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research CTORresearch.disclaimer